Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine Dicarboxamide SCHEMBL229425 | 0.85 | TSHR (0.59) | PIM1KDM4EALOX15TSHRACMSD | |
| Pyridine Dicarboxamide SCHEMBL29587789 | 0.85 | TSHR (0.59) | PIM1KDM4EALOX15TSHRACMSD | |
| Pyridine Dicarboxamide SCHEMBL38659131 | 0.83 | TSHR (0.56) | PIM1KDM4EALOX15TSHRACMSD | |
| Pyridine Dicarboxamide SCHEMBL29501171 | 0.83 | TSHR (0.56) | PIM1KDM4EALOX15TSHRACMSD | |
| Pyridine Dicarboxamide SCHEMBL29031925 | 0.83 | TSHR (0.56) | PIM1KDM4EALOX15TSHRACMSD | |
| Pyridine Dicarboxamide SCHEMBL15347496 | 0.83 | TSHR (0.56) | PIM1KDM4EALOX15TSHRACMSD | |
| SCHEMBL221380 | 0.82 | KDM4E (0.70) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL29956648 | 0.82 | KDM4E (0.70) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31045457 | 0.80 | ALDH1A1 (0.47) | PIM1PIM3KDM4EALOX15TSHR | |
| SCHEMBL13159666 | 0.80 | ALDH1A1 (0.47) | PIM1PIM3KDM4EALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116410441-A | Water-based polyurethane-acrylate emulsion and preparation method thereof | 万华化学集团股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20210254158-A1 | METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2021-08-19 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007457-A2 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007481-A2 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | AMGEN INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | PIM1 4097/4885PIM3 4329/4885KDM4E 2772/4885 |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PIM1 2933/4885PIM3 3231/4885KDM4E 922/4885 |
| US-20040204437-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PIM1 1472/4885PIM3 1881/4885KDM4E 1056/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | PIM1 612/4885PIM3 682/4885KDM4E 825/4885 |
| US-20030134836-A1 | Substituted arylamine derivatives and methods of use | NAT1, AADAC, AHR | PIM1 1472/4885PIM3 1881/4885KDM4E 1056/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | PIM1 2443/4885PIM3 2690/4885KDM4E 850/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PIM1 489/4885PIM3 805/4885KDM4E 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.